Bellerophon Therapeutics Would Be Delisted From NASDAQ At The Opening Of Business On July 28, 2023, Unless The Company Timely Requests A Hearing Before NASDAQ Hearings Panel To Address The Deficiencies And Present A Plan To Regain Compliance - 8K
Bellerophon Therapeutics Would Be Delisted From NASDAQ At The Opening Of Business On July 28, 2023, Unless The Company Timely Requests A Hearing Before NASDAQ Hearings Panel To Address The Deficiencies And Present A Plan To Regain Compliance - 8K
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.